{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T22:28:04Z","timestamp":1772144884910,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Ischemic stroke is the second most common chronic disease worldwide and is associated with high morbidity and mortality. Thromboembolism and platelet aggregation are the most characteristic features of stroke. Other than aspirin, no standard, accepted, or effective treatment for acute ischemic stroke has been established. Consequently, it is essential to identify novel therapeutic compounds for this condition.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this study, novel ozagrel\/paeonol-containing codrugs were synthesized and characterized using <jats:sup>1<\/jats:sup>H-NMR, <jats:sup>13<\/jats:sup>C-NMR, and mass spectroscopy. Their antiplatelet aggregation activity was evaluated, with compound PNC<jats:sub>3<\/jats:sub> found to exhibit the best effect. Subsequently, studies were conducted to assess its neuroprotective effect, pharmacokinetic properties and model its binding mode to P2Y12 and TXA2, two proteins critical for platelet aggregation.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The results indicated that PNC3 has good bioavailability and exerts protective effects against oxygen-glucose deprivation injury in PC12 cells. Molecular docking analysis further demonstrated that the compound interacts with residues located in the active binding sites of the target proteins.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The codrugs synthesized in this study display promising pharmacological activities and have the potential for development as an oral formulation.<\/jats:p>","DOI":"10.3389\/fphar.2024.1362857","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:37:05Z","timestamp":1710823025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Design, synthesis, and evaluation of the novel ozagrel\u2013paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent"],"prefix":"10.3389","volume":"15","author":[{"given":"Chijing","family":"Zuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiyin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/17425247.2016.1187598","article-title":"The codrug approach for facilitating drug delivery and bioactivity","volume":"13","author":"Aljuffali","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1212\/CON.0000000000000416","article-title":"Stroke epidemiology and risk factor management","volume":"23","author":"Amy Guzik","year":"2017","journal-title":"Contin. (Minneap Minn)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"106827","DOI":"10.1016\/j.vph.2020.106827","article-title":"Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia","volume":"137","author":"Bhatia","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.1038\/s41598-021-87431-4","article-title":"Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents","volume":"11","author":"Chua","year":"2021","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neulet.2013.12.060","article-title":"UPEI-300, a conjugate of lipoic acid and edaravone, mediates neuroprotection in ischemia\/reperfusion","volume":"561","author":"Connell","year":"2014","journal-title":"Neurosci. Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1160\/th06-12-0725","article-title":"Hyperresponsiveness of platelets in ischemic stroke","volume":"97","author":"Daniel","year":"2017","journal-title":"Thrombosis Haemostasis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1080\/14786419.2022.2036145","article-title":"Design, synthesis, and in vitro antiplatelet aggregation activities of taiwanin C","volume":"37","author":"Daron","year":"2022","journal-title":"Nat. Prod. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejps.2010.09.014","article-title":"Codrug: an efficient approach for drug optimization","volume":"41","author":"Das","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/s0140-6736(16)30962-x","article-title":"Stroke","volume":"389","author":"Hankey","year":"2017","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1161\/circresaha.116.308427","article-title":"Cerebral vascular disease and neurovascular injury in ischemic stroke","volume":"120","author":"Hu","year":"2017","journal-title":"Circulation Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1211\/0022357023150","article-title":"Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in Guinea-pigs","volume":"56","author":"Ishitsuka","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1254\/jphs.09128SC","article-title":"A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid\u2013induced lung injury in Guinea pigs","volume":"111","author":"Ishitsuka","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.cmi.2022.04.018","article-title":"Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1248\/cpb.13-00042","article-title":"Prediction of compatibility between ozagrel sodium preparation for injection and calcium on the basis of the solubility product","volume":"65","author":"Mio","year":"2013","journal-title":"Chem. Pharm. Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.me.31.020180.000513","article-title":"Prostaglandins and platelets","volume":"31","author":"Mustard","year":"1980","journal-title":"Annu. Rev. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/molecules23051117","article-title":"Synthesis of water-soluble amino functionalized multithiacalix[4]arene via quaternization of tertiary amino groups","volume":"23","author":"Nosov","year":"2018","journal-title":"Molecules"},{"key":"B18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.brainres.2014.12.051","article-title":"Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model","volume":"1599","author":"Park","year":"2015","journal-title":"Brain Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1248\/yakushi.128.1845","article-title":"Preparation and prodrug studies of quercetin pentabenzensulfonate","volume":"128","author":"Peng","year":"2008","journal-title":"Pharm. Soc. Jpn."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/bloodadvances.2020002888","article-title":"Platelets as drivers of ischemia\/reperfusion injury after stroke","volume":"5","author":"Shaik","year":"2021","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/cir.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.atherosclerosis.2012.03.008","article-title":"Platelets enter atherosclerotic plaque via intraplaque microvascular leakage and intraplaque hemorrhage: a histopathological study in carotid plaques","volume":"222","author":"Van Lammeren","year":"2012","journal-title":"Atherosclerosis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.07.044","article-title":"Ozagrel for patients with noncardioembolic ischemic stroke: a propensity score-matched analysis","volume":"25","author":"Wada","year":"2016","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cbdd.14145","article-title":"Design, synthesis, and anticancer evaluation of N6\u2010hydrazone purine derivatives with potential antiplatelet aggregation activity","volume":"101","author":"Wei","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"B25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ptr.8049","article-title":"Protective mechanism of Paeonol on central nervous system","volume":"23","author":"Wu","year":"2023","journal-title":"Phytotherapy Res. PTR"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2728","DOI":"10.6061\/clinics\/2021\/e2728","article-title":"Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window","volume":"76","author":"Zhang","year":"2021","journal-title":"Clinics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"608221","DOI":"10.3389\/fphar.2020.608221","article-title":"Synthesis of paeonol-ozagrel conjugate: structure characterization and in vivo anti-ischemic stroke potential","volume":"11","author":"Zhang","year":"","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1179\/1743132812y.0000000022","article-title":"Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials","volume":"34","author":"Zhang","year":"2013","journal-title":"Neurological Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.intimp.2019.04.033","article-title":"Paeonol: pharmacological effects and mechanisms of action","volume":"72","author":"Zhang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1925363","DOI":"10.1080\/00268976.2021.1925363","article-title":"The theoretical investigation on properties of paeonol and its isomers","volume":"119","author":"Zhang","year":"","journal-title":"Mol. Phys."},{"key":"B31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3892\/etm.2021.10004","article-title":"Paeoniflorin protects PC12 cells from oxygen-glucose deprivation\/reoxygenation-induced injury via activating JAK2\/STAT3 signaling","volume":"21","author":"Zhang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.3892\/etm.2018.5893","article-title":"Protective effects of paeonol on subacute\/chronic brain injury during cerebral ischemia in rats","volume":"15","author":"Zhao","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.intimp.2016.11.010","article-title":"Study on the physicochemical properties and anti-inflammatory effects of paeonol in rats with TNBS-induced ulcerative colitis","volume":"42","author":"Zong","year":"2017","journal-title":"Int. Immunopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:37:08Z","timestamp":1710823028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":33,"alternative-id":["10.3389\/fphar.2024.1362857"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1362857","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"article-number":"1362857"}}